InvestSMART

Lumos Diagnostics Holdings Limited (ASX:LDX)

ALERT: Price-sensitive ASX Announcement for LDX
Current share price for LDX : $0.115 0.005 (4.55%)+
Announcement
Release
27 Jul 2026 9:55AM
Price at Release
$0.110
Full Release
download
Summary
Lumos Diagnostics released its Quarterly Activity Statement and Appendix 4C Cash Flow Report for Q4 FY26. The company reported a total revenue increase of 6% for FY26 to US$13.2 million, driven by a 135% growth in its Products division due to the success of FebriDx®. The U.S. expansion of FebriDx®, now available in over 300,000 locations following a CLIA waiver, played a significant role in this growth. Operating cash inflow was US$2.7 million, and the cash balance stood at US$15.4 million as of 30 June 2026. Key achievements include substantial milestone payments from PHASE Scientific and BARDA, and ongoing development projects with Hologic, set to extend to 2028.
Key Points
  • Lumos Diagnostics' FY26 revenue rose to US$13.2 million, a 6% increase.
  • FebriDx® achieved an 875% rise in revenue, significantly contributing to product sales.
  • The company received US$5 million from PHASE Scientific and US$0.5 million from BARDA as milestone payments.
  • FebriDx® received a CLIA waiver, expanding its U.S. market access significantly.
  • The cash balance was US$15.4 million at the end of June 2026.
  • Ongoing projects with Hologic have extended timelines to June 2028.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.